09:07 AM EDT, 05/19/2025 (MT Newswires) -- Prime Medicine ( PRME ) on Monday reported positive initial data from the first patient dosed in its ongoing Phase 1/2 clinical study of PM359 for the potential treatment of chronic granulomatous disease.

Preliminary results from the first patient in the study showed that the drug was well-tolerated, showed rapid engraftment, and restored NADPH oxidase activity to levels well above the threshold of clinical benefit, the company said.

Chronic granulomatous disease is a rare hereditary genetic disease that causes recurring, debilitating and often life-threatening infections.

Shares of the company were up nearly 19% in recent premarket activity.